Biohaven (BHVN) vs Braveheart Bio (BRVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biohaven is the larger company by market cap ($1.82 billion vs $1.80 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | BRVE |
|---|---|---|
| Share price | $12.08 | $20.02 |
| Market cap | $1.82B | $1.80B |
| 1-day change | +1.26% | +4.87% |
| YTD return | +5.67% | — |
| 1-year return | -22.23% | — |
| EPS (TTM) | $-4.56 | $-6.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-738.82M | — |
| 52-week high | $18.57 | $32.00 |
| 52-week low | $7.48 | $17.86 |
| Distance from 52-week high | -34.93% | -37.44% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +76.08% | +126.02% |
| Average volume | 2.62M | 558.38K |
| Shares outstanding | 151.04M | 90.04M |
| Employees | 274 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
BHVN vs BRVE FAQ
Which is bigger, Biohaven or Braveheart Bio?
Biohaven (BHVN) is larger, with a market capitalization of $1.82B compared with $1.80B for Braveheart Bio (BRVE).
Are Biohaven and Braveheart Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.